PMVP · PMV Pharmaceuticals, Inc.
$1.40
-0.04 (-2.78%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that the Company's current available cash, cash equivalents and marketable securities may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$74.84M
Shares
53.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.40
Open$1.45
Day$1.40–1.51
52W close$1.02–1.80
Avg vol 30d612K
Short int2.3M · 4.2% float · 8.5d
Short vol45%
Last earningsMay 27, 2025
DataSep 2020–Sep 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$75.22M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$79.43M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.6%
Year over year · more shares
Price change (1Y)
+13.8%
Trailing year
Short interest
4.2%
Latest settlement · 8.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Bearish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
+11%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
49%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
−5%
trailing
YTD return
+12%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.24% of float · ▲ +1.0% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
64 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
−30%
Y/Y
Free cash flow
$-73.6M
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
49%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.24% of float · ▲ +1.0% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
64 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 49%
Range high $2
vs 200-day avg +10%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMVP
this stock
PMV Pharmaceuticals, Inc.
|
$74.84M | +12.0% | — | — | 4.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMVP | +12.9% | +15.2% | -4.8% | +15.7% | +12.0% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +14.1% | +17.0% | -22.6% | +16.1% | -0.1% |
Key facts
CIK
1699382
CUSIP
69353Y103
13F (30d)
35 filings
35 filers
Visit website
Investor relations